Overview
BioMaxima S.A. is a Polish, Warsaw Stock Exchange-listed manufacturer of microbiological media, reagents and in vitro diagnostics equipment. The company provides microbiology, molecular diagnostics and cell culture products, laboratory diagnostics and disposable materials. It also runs training courses for laboratories, including validation and verification of microbiological test methods and Legionella diagnostics.
Financials
Revenue history (in m)
Data and insights are generated automatically based on financial statements and may contain errors. This analysis is for informational purposes only and does not constitute an official assessment of the company's credibility or business advice.
Stock quotes
- Open
- PLN 9.97
- High
- PLN 10.04
- Low
- PLN 9.97
- Volume
- 134
- Avg. vol.
- 2.02K
- Market cap
- PLN 42.10M
- P/E ratio
- 52.84
- EPS
- PLN 0.19
- Shares outstanding
- 4.19M
- 52-week
- PLN 9.78 – 10.10
- Dividend yield
- 4.98%
- Dividend
- PLN 0.50
- Ex dividend date
- Jun 16, 2023
- ISIN
- PLBIOMX00015
- Exchange
- GPW Main Market
Quarterly results
| Period | Revenue | EBIT | Net profit |
|---|---|---|---|
| Q2 2026 | USD 3.75m | USD 207.73k | USD 97.78k |
| Q1 2026 | USD 4.27m | USD 146.14k | USD 88.60k |
| Q4 2025 | USD 4.33m | USD 197.64k | USD 106.23k |
| Q3 2025 | USD 3.51m | USD -5.78k | USD -76.34k |
Results for Q3 2026:Nov 30, 2026
Statistics
How the company ranks by revenue within its industry, region and across Poland in 2025.
Results vs industry
Industry
Bank accounts
Registered as a VAT taxpayer on 2002-09-16. Active
91 1160 2202 0000 0000 8606 5811
79 1050 1953 1000 0090 3132 2168- 85 1160 2202 0000 0003 4504 3406
Debt
No entries in the National Debtors Register (KRZ). No proceedings in KRZ
MSiG notices
| Publication date | Event | |
|---|---|---|
| Jan 26, 2011 | Merger plan |
Public aid
44 public aid cases recorded, with a total value of $4,945,134.
| Grant date | Purpose | Gross amount | Granting body | |
|---|---|---|---|---|
| Jun 25, 2026 | De minimis aid (in accordance with Commission Regulation 2023/2831) | $14,675$14,675 | Prezes Banku Gospodarstwa Krajowego | |
| Jun 25, 2026 | De minimis aid (in accordance with Commission Regulation 2023/2831) | $11,217$11,217 | Prezes Banku Gospodarstwa Krajowego | |
| Jun 25, 2026 | De minimis aid (in accordance with Commission Regulation 2023/2831) | $9,581$9,581 | Prezes Banku Gospodarstwa Krajowego |
European Funds
20 projects co-financed from European Funds recorded, with total EU co-financing of $5,635,659.
| Start | Project | EU co-financing | Programme | |
|---|---|---|---|---|
| 2026-07-01 | Wdrożenie wyników prac B+R w Biomaxima nad nowymi gradientowymi testami paskowymi MIC | $259.8K$259,789 | Fundusze Europejskie dla Lubelskiego 2021-2027 | |
| 2025-11-02 | Promocja produktów Biomaxima poprzez udział w targach zagranicznych | $70,856$70,856 | Fundusze Europejskie dla Lubelskiego 2021-2027 | |
| 2025-10-01 | Zwiększenie konkurencyjności Biomaxima poprzez wdrożenie wyników prac B+R nad nowymi bibułowymi krążkami antybiotykowymi | $275.7K$275,699 | Fundusze Europejskie dla Lubelskiego 2021-2027 |
Tenders
986 tenders recorded as contractor: 702 national ($8,779,582) and 284 EU ($120,886,323).
| Publication date | Subject | Amount | Contracting authority | |
|---|---|---|---|---|
| Oct 14, 2026 | Dostawa drobnego sprzętu laboratoryjnego, testów immunochromatograficznych, odczynników i testów z zakresu analityki ogólnej, kiły, lekowrażliwości, wykrywania przeciwciał w diagnostyce autoimmunologii metodą elisa wraz z dzierżawą analizatora wraz z analizatorem jako beckapu | –– | Wojewódzki Szpital Specjalistyczny Im. Najświętszej Maryi Panny | |
| Oct 12, 2026 | Dzierżawa analizatorów i aparatów wraz z zakupem materiałów zużywalnych oraz zakup indywidualnych materiałów zużywalnych dla Zakładu Genetyki | –– | Szpital Uniwersytecki Nr 1 Im. Dr. A. Jurasza w Bydgoszczy | |
| Oct 9, 2026 | Dzierżawa analizatorów i aparatów wraz z zakupem materiałów zużywalnych oraz zakup indywidualnych materiałów zużywalnych dla Zakładu Genetyki | –– | Szpital Uniwersytecki Nr 1 Im. Dr. A. Jurasza w Bydgoszczy |
Public sector contracts
Biomaxima is the contractor in 366 public sector contracts, worth PLN 3.11m in total. They were signed with 151 public buyers. The largest number (4) were signed with Radomski Szpital Specjalistyczny Im. Dr Tytusa Chałubińskiego.
| Public buyer | Value | |
|---|---|---|
| Wojewódzka Stacja Sanitarno-Epidemiologiczna w Krakowie | PLN 290.00 | |
| Wojewódzka Stacja Sanitarno-Epidemiologiczna w Krakowie | PLN 2,238 | |
| Uniwersytet Mikołaja Kopernika w Toruniu | PLN 3,135 | |
| Uniwersytecki Szpital Kliniczny w Białymstoku | PLN 560.00 | |
| Uniwersytet Marii Curie-Skłodowskiej | PLN 700.68 |
Public procurement disputes (KIO)
Biomaxima has been a party to 3 cases before the National Appeal Chamber (since 2020). In 3 cases it joined the proceedings as a participant.
Trademarks
Biomaxima holds 1 active trademark registered with the Polish Patent Office. The first mark was filed in 2018.
| Mark | Protected until | |
|---|---|---|
| BIOMAXIMA | May 21, 2028 |
Regulatory authorisations
| Authority | Type | Status | |
|---|---|---|---|
 BDO | BDO register entry | Active |
Authorized Representatives
Manner of representation
In the case of a multi-member management board, the joint action of two members of the management board or of one member of the management board jointly with a commercial proxy is required to submit declarations and to sign on behalf of the company.
Supervisory board
Beneficial owners
No beneficial owners recorded for the company Biomaxima.
Competitors
| Name | Revenue | Website | ||
|---|---|---|---|---|
| Techmotsp. z o.o. | $7,176,732.37 | tech-mot.pl | ||
| Nanomaxsp. z o.o. | $1,764,224.34 | nanomax.pl |
Change history
| Date | Event | |
|---|---|---|
| 2023-09-01 | Share capital change (4,373,305.00 PLN → 4,193,118.00 PLN) | |
| 2023-04-05 | Share capital change (4,328,500.00 PLN → 4,373,305.00 PLN) | |
| 2022-03-31 | Share capital change (4,320,000.00 PLN → 4,328,500.00 PLN) | |
| 2021-02-26 | Share capital change (4,210,000.00 PLN → 4,320,000.00 PLN) | |
| 2020-04-28 | Share capital change (3,730,000.00 PLN → 4,210,000.00 PLN) |
FAQ
Last updated: 2026-06-19